Adherence to Fixed-Combination Versus Unfixed Travoprost 0.004%/Timolol 0.5% for Glaucoma or Ocular Hypertension: a Randomized Trial
To assess adherence to treatment with fixed-combination travoprost 0.004%/timolol 0.5% (TTFC) compared with separate containers of travoprost 0.004% and timolol 0.5% (TRAV+TIM; unfixed) using electronic dosing aids (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - December 15, 2016 Category: Opthalmology Authors: Howard S. Barnebey, Alan L. Robin Tags: Original Articles Source Type: research
Efficacy and patient tolerability of preservative ‐free latanoprost compared with preservative prostaglandin analogs in patients with ocular hypertension or glaucoma
ConclusionsThese preliminary results show that PF latanoprost has better subjective and objective local tolerance than preservative PGA. Switching to PF latanoprost seems to maintain IOP at the same level as preservative PGA but improve ocular surface toxicity. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 13, 2016 Category: Opthalmology Authors: A. El Ameen, G. Vandermeer, P.J. Pisella Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research
Prolonged Ocular Inflammation in Endotoxin-Induced Uveitis in Lysosomal Phospholipase A2-Deficient Mice.
CONCLUSIONS: These results confirm that LPLA2 plays a significant role in the control of IOP during mouse ocular development or with ocular inflammation by facilitating the digestion of intraocular insoluble materials.
PMID: 27612621 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - September 8, 2016 Category: Opthalmology Authors: Sawada K, Hiraoka M, Abe A, Kelly R, Shayman JA, Ohguro H Tags: Curr Eye Res Source Type: research
Does the intraocular pressure-lowering effect of prostaglandin analogues continue over the long term?
AbstractThe purpose of the study is to assess the changes in the long-term effects of prostaglandin analogues (PGAs) on intraocular pressure (IOP) reduction in patients with primary open-angle glaucoma (POAG). Data of POAG patients treated with latanoprost (0.005 %), travoprost (0.004 %), or bimatoprost (0.03 %) as the first line treatment for 5 years or more were retrospectively evaluated. Baseline ophthalmic assessment values were recorded together with the IOP at the 6th month, 1st year, and then annually. The 79 patients included 33 (41.8 %) men an d 46 (58.2 %) women. There were 34 (43.0 %) patients using lata...
Source: International Ophthalmology - August 8, 2016 Category: Opthalmology Source Type: research
Effect of Travoprost and Nonsteroidal Anti-Inflammatory Drug on Diurnal Intraocular Pressure in Normal Subjects with Low-Teen Baseline Intraocular Pressure
Journal of Ocular Pharmacology and Therapeutics Jul 2016, Vol. 32, No. 6: 365-370. (Source: Journal of Ocular Pharmacology and Therapeutics)
Source: Journal of Ocular Pharmacology and Therapeutics - July 14, 2016 Category: Opthalmology Authors: Rei SakataToshihiro SakisakaHiroshi MatsuoKazunori MiyataMakoto Aihara Source Type: research
Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost
Purpose: To assess the effect of switching 1 eye to topical travoprost 0.004% preserved with SofZia (TRAVATAN Z solution) in patients who had chronic superficial punctate keratitis (SPK) in both eyes treated with benzalkonium chloride–preserved latanoprost 0.005% (XALATAN).
Methods: This was a prospective, randomized, controlled, multicenter, open-label, comparative 3-month follow-up study. Patients with open-angle glaucoma or ocular hypertension who received XALATAN monotherapy for at least 3 months and had SPK in both eyes were enrolled at 9 facilities. For each patient, 1 eye was randomly selected and switched to TRA...
Source: Journal of Glaucoma - June 1, 2016 Category: Opthalmology Tags: Online Articles: Original Studies Source Type: research
Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension
In conclusion, BAK-preserved tafluprost ophthalmic solution 0.0015 % remains a useful option for the treatment of Asian patients with glaucoma and ocular hypertension. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - May 24, 2016 Category: Drugs & Pharmacology Source Type: research
Comparison of Latanoprost, Travoprost, and Bimatoprost on Adherence, Persistence, and Pattern of Initial Therapy in Glaucoma and Ocular Hypertension: An Administrative Claims Database Analysis
Glaucoma causes an atrophy of the optic nerve with increased intraocular pressure (IOP), which can lead to blindness. When topical treatment fails to lower IOP adequately, the patient may add or change medications or have surgery/laser treatment. Prostaglandin therapy is recommended as initial therapy. The purpose of this study was to compare medication adherence, persistence, and post-index patterns between latanoprost, bimatoprost, and travoprost as initial therapies for glaucoma/ocular hypertension. (Source: Value in Health)
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: JH Heo, KL Rascati Tags: SENSORY SYSTEMS DISORDERS – Patient-Reported Outcomes & Patient Preference Studies Source Type: research
Prostaglandins in the eye: Function, expression, and roles in glaucoma.
Authors: Doucette LP, Walter MA
Abstract
Prostaglandins are small pro-inflammatory molecules derived from arachidonic acid that play roles in a multitude of biological processes including, but not limited to, inflammation, pain modulation, allergies, and bone formation. Prostaglandin analogues are the front-line medications for the treatment of glaucoma, a condition resulting in blindness due to the death of retinal ganglion cells. These drugs act by lowering intraocular pressure (IOP), a major risk factor for glaucoma. The currently used prostaglandin analogues (latanoprost, bimatoprost, tafluprost, and t...
Source: Ophthalmic Genetics - April 15, 2016 Category: Opthalmology Tags: Ophthalmic Genet Source Type: research
Prostaglandin analogues: current treatment option for glaucoma
Abstract
Glaucoma is a progressive optic neuropathy and is the world’s second leading cause of blindness. It is a multifactorial disease that is etiologically complex where elevated intraocular pressure in the eye is the major risk factor. Prostaglandin analogues are the first-line drugs in today’s glaucoma therapy. These are 20 carbon atom naturally occurring fatty acid derivatives biosynthesized from arachidonic acid. They involve COX pathway where arachidonic acid interacts with COX in the presence of oxygen and heme and produces PGG2. It is a cyclic endoperoxide with very short half life and gener...
Source: Medicinal Chemistry Research - April 6, 2016 Category: Chemistry Source Type: research
Acute Corneal Toxicity of Combined Antiglaucoma Topical Eyedrops.
CONCLUSION: The corneal toxicity of latanoprost/timolol with 0.02% BAC is greater than that of travoprost/timolol with polyquaternium-1 and dorzolamide/timolol with 0.005% BAC. Latanoprost/timolol contains 0.02% BAC, which may be responsible for the corneal toxicity.
PMID: 27002346 [PubMed - as supplied by publisher] (Source: Current Eye Research)
Source: Current Eye Research - March 21, 2016 Category: Opthalmology Authors: Mohamed YH, Uematsu M, Onizuka N, Ueki R, Inoue D, Fujikawa A, Sasaki H, Kitaoka T Tags: Curr Eye Res Source Type: research
Effect of Antiglaucoma Medicine on Intraocular Pressure in DBA/2J Mice
Conclusion: DBA/2J mice are a useful animal model to study the effects of antiglaucoma therapy.Ophthalmic Res 2016;55:205-211 (Source: Ophthalmic Research)
Source: Ophthalmic Research - March 5, 2016 Category: Opthalmology Source Type: research
The Interaction of Nepafenac and Prostaglandin Analogs in Primary Open-angle Glaucoma Patients
Conclusions: Nepafenac potentiates the IOP-lowering effects of 3 different PG analogs in POAG patients. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - March 1, 2016 Category: Opthalmology Tags: Online Articles: Original Studies Source Type: research
Time Course of Prostaglandin Analog-related Conjunctival Hyperemia and the Effect of a Nonsteroidal Anti-inflammatory Ophthalmic Solution
Conclusions: The use of NSAID ophthalmic solution had almost no impact on PG analog-related conjunctival hyperemia. This partly suggests that the action mechanism of endogenous PG after administrating PG analog might be no correlation with conjunctival hyperemia. (Source: Journal of Glaucoma)
Source: Journal of Glaucoma - March 1, 2016 Category: Opthalmology Tags: Online Articles: Original Studies Source Type: research
A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%
To evaluate the safety and efficacy of adding fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) as adjunctive therapy to travoprost 0.004% (TRAV) in patients with open-angle glaucoma or ocular hypertension (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - February 29, 2016 Category: Opthalmology Authors: Robert Feldman, Gregory Katz, Matthew McMenemy, Douglas A. Hubatsch, Tony Realini Tags: Original Articles Source Type: research
